2012年蛋白和抗体类药物销售额一览（List of protein and antibody drugs sales in 2012）.docVIP

下载本文档

12
0
约1.27万字
约 15页
2017-09-08 发布于河南
举报
版权申诉

2012年蛋白和抗体类药物销售额一览（List of protein and antibody drugs sales in 2012）.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

2012年蛋白和抗体类药物销售额一览（List of protein and antibody drugs sales in 2012）

2012年蛋白和抗体类药物销售额一览（List of protein and antibody drugs sales in 2012） AC]2012 protein and antibody drugs sales list of 7 people participated 1.TNF antibody 2012 sales: $26 billion 680 million; 2011 sales: $24 billion 40 million Indication: rheumatoid arthritis (1) adalimumab (adalimumab):Humira, TNF alpha monoclonal antibody, Abbott/Eisai, sales of $9 billion 534 million in 2012 (2) etanercept (etanercept),:Enbrel, TNF-, mAb, and Amgen/Pfizer/Takeda, with sales of $8 billion 406 million in 2012 (3) infliximab (infliximab),:Remicade, TNF- mAb, Centocor/Merck/Mitsubishi Tanabe, and 2012 sales of $7 billion 468 million (4) golimumab (golimumab):Simponi, TNF alpha monoclonal antibody, Merck/Centocor/Mitsubishi Tanabe, 2012 sales of $654 million (5) (certolizumab, pegol),:Cimzia, TNF, - mAb, UCB, Pharma, in 2012 sales of $613 million 2. cancer antibodies 2012 sales: $23 billion 740 million; 2011 sales: $21 billion 380 million Indications: lymphoma, breast cancer, colorectal cancer, lung cancer, leukemia (1) rituximab (rituximab),:Rituxan/MabThera, CD20- monoclonal antibodies, Genentech, non Hodgkins lymphoma, and 2012 sales of $7 billion 143 million (2) trastuzumab (trastuzumab),:Herceptin, HER2- mAb, Genentech, HER2 positive breast cancer, 2012 sales of $6 billion 272 million (3) bevacizumab (bevacizumab),:Avastin, VEGF- monoclonal antibodies, Genentech, colorectal cancer, and non-small cell lung cancer, with sales of $6 billion 139 million in 2012 (4) cetuximab (cetuximab),:Erbitux, EGFR- monoclonal antibodies, Eli, Lilly/Bristol-Myers, Squibb/Merck, Serono, colorectal cancer, and 2012 sales of $1 billion 874 million (5) denosumab (denosumab):Xgeva, RANKL- mAb, Amgen/Daiichi Sankyo, bone cancer, sales of $748 million in 2012 (6) ipilimumab,:Yervoy, CD152- monoclonal antibodies, Bristol-Myers, Squibb, and multiple myeloma, with sales of $748 million in 2012 (7) panitumumab (panitumumab):Vectibix, EGFR- mAb, Takeda/Amgen, colorectal cancer, 2012 sales of $547 million (8)